An engineered xCas12i with high activity, high specificity, and broad PAM range
Accepted date: 19 Oct 2022
Published date: 15 Jul 2023
Copyright
Hainan Zhang , Xiangfeng Kong , Mingxing Xue , Jing Hu , Zikang Wang , Yinghui Wei , Haoqiang Wang , Jingxing Zhou , Weihong Zhang , Mengqiu Xu , Xiaowen Shen , Fengcai Yin , Zhiyuan Ai , Guangyan Huang , Junhui Xia , Xueqiong Song , Hengbin Li , Yuan Yuan , Jinhui Li , Na Zhong , Meiling Zhang , Yingsi Zhou , Hui Yang . An engineered xCas12i with high activity, high specificity, and broad PAM range[J]. Protein & Cell, 2023 , 14(7) : 538 -543 . DOI: 10.1093/procel/pwac052
| 1 |
Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 2020;38:824–844.
|
| 2 |
Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 2014;30:1473–1475.
|
| 3 |
Bock C, Datlinger P, Chardon F et al. High-content CRISPR screening. Nat Rev Methods Primers 2022;2:9.
|
| 4 |
Bravo JPK, Liu M-S, Hibshman GN et al. Structural basis for mismatch surveillance by CRISPR-Cas9. Nature 2022;603:343–347.
|
| 5 |
Chen Y, Hu Y, Wang X et al. Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing. Innovation (Camb) 2022;3:100264.
|
| 6 |
Doudna JA. The promise and challenge of therapeutic genome editing. Nature 2020;578:229–236.
|
| 7 |
Gillmore JD, Gane E, Taubel J et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021;385: 493–502.
|
| 8 |
Kleinstiver BP, Sousa AA, Walton RT et al. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol 2019;37:276–282.
|
| 9 |
McGaw C, Garrity AJ, Munoz GZ et al. Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing. Nat Commun 2022;13:2833.
|
| 10 |
Richter MF, Zhao KT, Eton E et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol 2020;38:883–891.
|
| 11 |
Yan WX, Hunnewell P, Alfonse LE et al. Functionally diverse type V CRISPR-Cas systems. Science 2019;363:88–91.
|
| 12 |
Yin J, Liu M, Liu Y et al. Optimizing genome editing strategy by primer-extension-mediated sequencing. Cell Discov 2019;5:18.
|
| 13 |
Wang X, Ding C, Yu W et al. Cas12a base editors induce efficient and specific editing with low DNA damage response. Cell Rep 2020;31:107723.
|
| 14 |
Zetsche B, Gootenberg JS, Abudayyeh OO et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 2015;163:759–771.
|
| 15 |
Zhang, Zuris JA, Viswanathan R et al. AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines. Nat Commun 2021;12:3908.
|
/
| 〈 |
|
〉 |